Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) Research & Development (2020 - 2025)

RxSight (RXST) has disclosed Research & Development for 6 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 3.28% year-over-year to $8.9 million, compared with a TTM value of $38.5 million through Dec 2025, up 12.17%, and an annual FY2025 reading of $38.5 million, up 12.17% over the prior year.
  • Research & Development was $8.9 million for Q4 2025 at RxSight, down from $9.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $10.4 million in Q1 2025 and bottomed at $5.4 million in Q3 2021.
  • Average Research & Development over 5 years is $7.6 million, with a median of $7.3 million recorded in 2023.
  • The sharpest move saw Research & Development rose 29.09% in 2021, then dropped 5.65% in 2022.
  • Year by year, Research & Development stood at $5.9 million in 2021, then grew by 12.95% to $6.7 million in 2022, then rose by 9.86% to $7.3 million in 2023, then rose by 25.42% to $9.2 million in 2024, then fell by 3.28% to $8.9 million in 2025.
  • Business Quant data shows Research & Development for RXST at $8.9 million in Q4 2025, $9.1 million in Q3 2025, and $10.2 million in Q2 2025.